Wensheng Fan, CEO and co-founder of Spectral AI, a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView � System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). DeepView ® records imaging data of the wound and uses an AI algorithm to predict wound healing patterns based on a large proprietary clinical database.
CEO and Co-Founder of Spectral AI, Inc., an award-winning, publicly traded predictive analytics company that develops proprietary artificial intelligence (AI) algorithms and optical technology for fast, accurate treatment decisions in wound care. Since launching the company in 2009, Wensheng has led engineering of the AI platform and DeepView ® product line, an FDA Breakthrough Designated medical imaging system, from concept and prototype to an FDA 501(K) cleared product, securing more than $150M in public and private funding to date.
Wensheng has 20 years of experience in pioneering market-disruptive natural speech recognition, real-time imaging systems, and AI driven predictive medical solutions. Before Spectral AI, Wensheng played pivotal roles in product development for start-up and large, international companies including Sensata Technologies, Navini Networks (acquired by Cisco), Precision Drilling Corporation (acquired by Weatherford), and Phillips Speech Processing.
Mr. Fan received his B.S.E.E. degree from Tsinghua University in Beijing, China and M.S.E.E. degree from Northeastern University in Boston.